In vitro study of imatinib and carboplatin in HNSCC

Alexander Sauter, Schultz Johannes, Rotunno Sarah, Erben Philipp, Hörmann Karl & Riedel Frank
Protein-tyrosins-kinases (PTK) are important targets for chemical agents that inhibit their activities. In HNSCC only the EGFR-PTK inhibitor gefitinib (Iressa®) has been studied extensively. The PTK inhibitor Imatinib (Glivec®, also known as STI571, Novartis, Basel, Switzerland) belongs to[for full text, please go to the a.m. URL]